Aptose Biosciences, Inc. - Common Shares (TSX:APS)

2.200 UNCHANGED

Streaming Delayed Price Updated: 10:46 AM EDT, Jun 17, 2026 Add to My Watchlist

Price and Volume

Volume	126
Open	2.200
Bid (Size)	2.200 (99)
Ask (Size)	2.360 (15)
Prev. Close	2.200
Today's Range	2.200 - 2.200
52wk Range	1.020 - 2.590
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation

June 15, 2026

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical

May 29, 2026

From Aptose Biosciences, Inc.

Via GlobeNewswire

Performance

YTD	+8.9%	+8.9%
1 Month	-5.6%	-5.6%
3 Month	-0.9%	-0.9%
6 Month	+0.9%	+0.9%
1 Year	+22.9%	+22.9%

More News

Aptose Reports First Quarter 2026 Results

May 13, 2026

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical

April 30, 2026

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights

March 31, 2026

From Aptose Biosciences, Inc.

Via GlobeNewswire

Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement

March 23, 2026

From Aptose Biosciences, Inc.

Via GlobeNewswire

Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arrangement with Hanmi Pharmaceutical

March 19, 2026

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Biosciences Announces Amendment to Arrangement Agreement and Details of Postponed Special Meeting of Shareholders

February 24, 2026

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC

December 19, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations

December 06, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical

November 19, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Reports Third Quarter 2025 Results

November 13, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting

November 03, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose and Hanmi Pharmaceutical Extend Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML

September 22, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML

October 16, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor

August 22, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial

August 18, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Reports Second Quarter 2025 Results

August 13, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy

August 06, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders

August 01, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML

July 15, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Upgraded to Trade on OTCQB Market

July 01, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Announces Deferral of Interest Payment

June 30, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML

June 20, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Aptose Provides Corporate Updates

June 17, 2025

From Aptose Biosciences, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Aptose Biosciences, Inc. - Common Shares publicly traded?

Yes, Aptose Biosciences, Inc. - Common Shares is publicly traded.

What exchange does Aptose Biosciences, Inc. - Common Shares trade on?

Aptose Biosciences, Inc. - Common Shares trades on the Toronto Stock Exchange

What is the ticker symbol for Aptose Biosciences, Inc. - Common Shares?

The ticker symbol for Aptose Biosciences, Inc. - Common Shares is APS on the Toronto Stock Exchange

What is the current price of Aptose Biosciences, Inc. - Common Shares?

The current price of Aptose Biosciences, Inc. - Common Shares is 2.200

When was Aptose Biosciences, Inc. - Common Shares last traded?

The last trade of Aptose Biosciences, Inc. - Common Shares was at 06/17/26 10:46 AM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.